207 related articles for article (PubMed ID: 31557131)
1. YAP1 oncogene is a context-specific driver for pancreatic ductal adenocarcinoma.
Tu B; Yao J; Ferri-Borgogno S; Zhao J; Chen S; Wang Q; Yan L; Zhou X; Zhu C; Bang S; Chang Q; Bristow CA; Kang Y; Zheng H; Wang H; Fleming JB; Kim M; Heffernan TP; Draetta GF; Pan D; Maitra A; Yao W; Gupta S; Ying H
JCI Insight; 2019 Nov; 4(21):. PubMed ID: 31557131
[TBL] [Abstract][Full Text] [Related]
2. Evolutionary routes and KRAS dosage define pancreatic cancer phenotypes.
Mueller S; Engleitner T; Maresch R; Zukowska M; Lange S; Kaltenbacher T; Konukiewitz B; Öllinger R; Zwiebel M; Strong A; Yen HY; Banerjee R; Louzada S; Fu B; Seidler B; Götzfried J; Schuck K; Hassan Z; Arbeiter A; Schönhuber N; Klein S; Veltkamp C; Friedrich M; Rad L; Barenboim M; Ziegenhain C; Hess J; Dovey OM; Eser S; Parekh S; Constantino-Casas F; de la Rosa J; Sierra MI; Fraga M; Mayerle J; Klöppel G; Cadiñanos J; Liu P; Vassiliou G; Weichert W; Steiger K; Enard W; Schmid RM; Yang F; Unger K; Schneider G; Varela I; Bradley A; Saur D; Rad R
Nature; 2018 Feb; 554(7690):62-68. PubMed ID: 29364867
[TBL] [Abstract][Full Text] [Related]
3. Loss of the wild-type KRAS allele promotes pancreatic cancer progression through functional activation of YAP1.
Yan H; Yu CC; Fine SA; Youssof AL; Yang YR; Yan J; Karg DC; Cheung EC; Friedman RA; Ying H; Chen EI; Luo J; Miao Y; Qiu W; Su GH
Oncogene; 2021 Dec; 40(50):6759-6771. PubMed ID: 34663879
[TBL] [Abstract][Full Text] [Related]
4. A nicotine-induced positive feedback loop between HIF1A and YAP1 contributes to epithelial-to-mesenchymal transition in pancreatic ductal adenocarcinoma.
Ben Q; An W; Sun Y; Qian A; Liu J; Zou D; Yuan Y
J Exp Clin Cancer Res; 2020 Sep; 39(1):181. PubMed ID: 32894161
[TBL] [Abstract][Full Text] [Related]
5. eIF5A-PEAK1 Signaling Regulates YAP1/TAZ Protein Expression and Pancreatic Cancer Cell Growth.
Strnadel J; Choi S; Fujimura K; Wang H; Zhang W; Wyse M; Wright T; Gross E; Peinado C; Park HW; Bui J; Kelber J; Bouvet M; Guan KL; Klemke RL
Cancer Res; 2017 Apr; 77(8):1997-2007. PubMed ID: 28381547
[TBL] [Abstract][Full Text] [Related]
6. YAP1-mediated pancreatic stellate cell activation inhibits pancreatic cancer cell proliferation.
Xiao Y; Zhang H; Ma Q; Huang R; Lu J; Liang X; Liu X; Zhang Z; Yu L; Pang J; Zhou L; Liu T; Wu H; Liang Z
Cancer Lett; 2019 Oct; 462():51-60. PubMed ID: 31352078
[TBL] [Abstract][Full Text] [Related]
7. Yap1 activation enables bypass of oncogenic Kras addiction in pancreatic cancer.
Kapoor A; Yao W; Ying H; Hua S; Liewen A; Wang Q; Zhong Y; Wu CJ; Sadanandam A; Hu B; Chang Q; Chu GC; Al-Khalil R; Jiang S; Xia H; Fletcher-Sananikone E; Lim C; Horwitz GI; Viale A; Pettazzoni P; Sanchez N; Wang H; Protopopov A; Zhang J; Heffernan T; Johnson RL; Chin L; Wang YA; Draetta G; DePinho RA
Cell; 2014 Jul; 158(1):185-197. PubMed ID: 24954535
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of Yes Associated Protein 1, an Independent Prognostic Marker in Patients With Pancreatic Ductal Adenocarcinoma, Correlated With Liver Metastasis and Poor Prognosis.
Salcedo Allende MT; Zeron-Medina J; Hernandez J; Macarulla T; Balsells J; Merino X; Allende H; Tabernero J; Ramon Y Cajal S
Pancreas; 2017 Aug; 46(7):913-920. PubMed ID: 28697132
[TBL] [Abstract][Full Text] [Related]
9. Central role of Yes-associated protein and WW-domain-containing transcriptional co-activator with PDZ-binding motif in pancreatic cancer development.
Rozengurt E; Eibl G
World J Gastroenterol; 2019 Apr; 25(15):1797-1816. PubMed ID: 31057295
[TBL] [Abstract][Full Text] [Related]
10. A combinatorial strategy using YAP and pan-RAF inhibitors for treating KRAS-mutant pancreatic cancer.
Zhao X; Wang X; Fang L; Lan C; Zheng X; Wang Y; Zhang Y; Han X; Liu S; Cheng K; Zhao Y; Shi J; Guo J; Hao J; Ren H; Nie G
Cancer Lett; 2017 Aug; 402():61-70. PubMed ID: 28576749
[TBL] [Abstract][Full Text] [Related]
11. Loss of Somatostatin Receptor Subtype 2 Promotes Growth of KRAS-Induced Pancreatic Tumors in Mice by Activating PI3K Signaling and Overexpression of CXCL16.
Chalabi-Dchar M; Cassant-Sourdy S; Duluc C; Fanjul M; Lulka H; Samain R; Roche C; Breibach F; Delisle MB; Poupot M; Dufresne M; Shimaoka T; Yonehara S; Mathonnet M; Pyronnet S; Bousquet C
Gastroenterology; 2015 Jun; 148(7):1452-65. PubMed ID: 25683115
[TBL] [Abstract][Full Text] [Related]
12. GNAS
Ideno N; Yamaguchi H; Ghosh B; Gupta S; Okumura T; Steffen DJ; Fisher CG; Wood LD; Singhi AD; Nakamura M; Gutkind JS; Maitra A
Gastroenterology; 2018 Nov; 155(5):1593-1607.e12. PubMed ID: 30142336
[TBL] [Abstract][Full Text] [Related]
13. lncRNA
Li N; Yang G; Luo L; Ling L; Wang X; Shi L; Lan J; Jia X; Zhang Q; Long Z; Liu J; Hu W; He Z; Liu H; Liu W; Zheng G
Clin Cancer Res; 2020 Apr; 26(7):1736-1748. PubMed ID: 31831555
[TBL] [Abstract][Full Text] [Related]
14. Epithelial cell transforming 2 is regulated by Yes-associated protein 1 and mediates pancreatic cancer progression and metastasis.
Li C; Peng Z; Wang Y; Lam G; Nissen N; Tang J; Yuan X; Lewis M; Greene MI; Pandol SJ; Wang Q
Am J Physiol Gastrointest Liver Physiol; 2021 Mar; 320(3):G380-G395. PubMed ID: 33501895
[TBL] [Abstract][Full Text] [Related]
15. MDH1 and MPP7 Regulate Autophagy in Pancreatic Ductal Adenocarcinoma.
New M; Van Acker T; Sakamaki JI; Jiang M; Saunders RE; Long J; Wang VM; Behrens A; Cerveira J; Sudhakar P; Korcsmaros T; Jefferies HBJ; Ryan KM; Howell M; Tooze SA
Cancer Res; 2019 Apr; 79(8):1884-1898. PubMed ID: 30765601
[TBL] [Abstract][Full Text] [Related]
16. SOX9 activity is induced by oncogenic Kras to affect MDC1 and MCMs expression in pancreatic cancer.
Zhou H; Qin Y; Ji S; Ling J; Fu J; Zhuang Z; Fan X; Song L; Yu X; Chiao PJ
Oncogene; 2018 Feb; 37(7):912-923. PubMed ID: 29059173
[TBL] [Abstract][Full Text] [Related]
17. Ribonucleoprotein HNRNPA2B1 interacts with and regulates oncogenic KRAS in pancreatic ductal adenocarcinoma cells.
Barceló C; Etchin J; Mansour MR; Sanda T; Ginesta MM; Sanchez-Arévalo Lobo VJ; Real FX; Capellà G; Estanyol JM; Jaumot M; Look AT; Agell N
Gastroenterology; 2014 Oct; 147(4):882-892.e8. PubMed ID: 24998203
[TBL] [Abstract][Full Text] [Related]
18. The RNA-Binding Protein HuR Posttranscriptionally Regulates the Protumorigenic Activator YAP1 in Pancreatic Ductal Adenocarcinoma.
Brown SZ; McCarthy GA; Carroll JR; Di Niro R; Pelz C; Jain A; Sutton TL; Holly HD; Nevler A; Schultz CW; McCoy MD; Cozzitorto JA; Jiang W; Yeo CJ; Dixon DA; Sears RC; Brody JR
Mol Cell Biol; 2022 Jul; 42(7):e0001822. PubMed ID: 35703534
[TBL] [Abstract][Full Text] [Related]
19. Oncogenic ERBB2 aberrations and KRAS mutations cooperate to promote pancreatic ductal adenocarcinoma progression.
Li Z; Shao C; Liu X; Lu X; Jia X; Zheng X; Wang S; Zhu L; Li K; Pang Y; Xie F; Lu Y; Wang Y
Carcinogenesis; 2020 Mar; 41(1):44-55. PubMed ID: 31046123
[TBL] [Abstract][Full Text] [Related]
20. Yes-associated protein mediates immune reprogramming in pancreatic ductal adenocarcinoma.
Murakami S; Shahbazian D; Surana R; Zhang W; Chen H; Graham GT; White SM; Weiner LM; Yi C
Oncogene; 2017 Mar; 36(9):1232-1244. PubMed ID: 27546622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
